• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Bellerophon Therapeutics Inc.

    2/12/24 3:44:59 PM ET
    $BLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BLPH alert in real time by email
    DEFA14A 1 tm245912d2_defa14a.htm DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No.__)

     

     

     

    Filed by the Registrant x

     

    Filed by a Party other than the Registrant ¨

     

    Check the appropriate box:

     

    ¨ Preliminary Proxy Statement

    ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ¨ Definitive Proxy Statement

    x Definitive Additional Materials

    ¨ Soliciting Material Pursuant to § 240.14a-12

     

    Bellerophon Therapeutics, Inc.

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    x No fee required.

    ¨ Fee paid previously with preliminary materials

    ¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     

     

     

    GRAPHIC

    1UPX Using a black ink pen, mark your votes with an X as shown in this example. Please do not write outside the designated areas. 03WCDB + + Please sign exactly as name(s) appears hereon. Joint owners should each sign. When signing as attorney, executor, administrator, corporate officer, trustee, guardian, or custodian, please give full title. Date (mm/dd/yyyy) — Please print date below. Signature 1 — Please keep signature within the box. Signature 2 — Please keep signature within the box. B Authorized Signatures — This section must be completed for your vote to count. Please date and sign below. q IF VOTING BY MAIL, SIGN, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. q 2024 Special Meeting Proxy Card A Proposals — The Board of Directors recommends a vote FOR Proposals 1 and 2. 1. The approval of the liquidation and dissolution of Bellerophon Therapeutics, Inc. (the “Company”) and the Plan of Liquidation and Dissolution (the “Plan of Dissolution”), which, if approved, will authorize the Company’s Board of Directors to liquidate and dissolve the Company in accordance with the Plan of Dissolution (the “Dissolution Proposal”); and 2. The approval of an adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Special Meeting to approve the Dissolution Proposal (the “Adjournment Proposal”). For Against Abstain For Against Abstain 1234 5678 9012 345 MMMMMMMMM 604848 MR A SAMPLE (THIS AREA IS SET UP TO ACCOMMODATE 140 CHARACTERS) MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND C 1234567890 J N T MMMMMMMMMMMM MMMMMMM If no electronic voting, delete QR code and control # Δ ≈ 000001MR A SAMPLE DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4 ADD 5 ADD 6 ENDORSEMENT_LINE______________ SACKPACK_____________ MMMMMMMMMMMMMMM C123456789 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext You may vote online or by phone instead of mailing this card. Online Go to www.envisionreports.com/BLPH or scan the QR code — login details are located in the shaded bar below. Save paper, time and money! Sign up for electronic delivery at www.envisionreports.com/BLPH Phone Call toll free 1-800-652-VOTE (8683) within the USA, US territories and Canada Votes submitted electronically must be received by 1:00 A.M., Eastern Time, on March 1, 2024. Your vote matters – here’s how to vote!

    GRAPHIC

    Small steps make an impact. Help the environment by consenting to receive electronic delivery, sign up at www.envisionreports.com/BLPH Notice of 2024 Special Meeting of Shareholders Proxy Solicited by Board of Directors for Special Meeting — March 1, 2024 Naseem Amin and Fred Hanuschek, or any of them, each with the power of substitution, are hereby authorized to represent and vote the shares of the undersigned, with all the powers which the undersigned would possess if personally present, at the Special Meeting of Shareholders of Bellerophon Therapeutics, Inc. to be held on March 1, 2024 or at any postponement or adjournment thereof. Shares represented by this proxy will be voted by the shareholder. If no such directions are indicated, the Proxies will have authority to vote FOR items 1 and 2. In their discretion, the Proxies are authorized to vote upon such other business as may properly come before the meeting. (Items to be voted appear on reverse side) Bellerophon Therapeutics, Inc. q IF VOTING BY MAIL, SIGN, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. q Change of Address — Please print your new address below. Comments — Please print your comments below. C Non-Voting Items + + Important notice regarding the Internet availability of proxy materials for the Special Meeting of Shareholders. The material is available at: www.envisionreports.com/BLPH 2024 Special Meeting Admission Ticket 2024 Special Meeting of Bellerophon Therapeutics, Inc. Shareholders Friday, March 1, 2024 at 11:00 AM Eastern Time Offices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. 919 Third Avenue, New York, NY 10022 Upon arrival, please present this admission ticket and photo identification at the registration desk.

    Get the next $BLPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BLPH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BLPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Bellerophon Therapeutics Inc. (Amendment)

      SC 13G/A - Bellerophon Therapeutics, Inc. (0001600132) (Subject)

      2/14/24 4:50:00 PM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Bellerophon Therapeutics Inc. (Amendment)

      SC 13G/A - Bellerophon Therapeutics, Inc. (0001600132) (Subject)

      2/14/24 4:00:25 PM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Bellerophon Therapeutics Inc.

      SC 13G - Bellerophon Therapeutics, Inc. (0001600132) (Subject)

      1/26/24 10:46:43 AM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease

      Trial did not meet its primary endpoint related to the change in moderate to vigorous physical activity INOpulse® was safe and well-tolerated, consistent with the overall safety profile demonstrated in Phase 2 and other INOpulse® programs in PH-COPD and PH-SarcoidosisCompany to host conference call and webcast with slides today at 8:30 AM ET WARREN, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced top-line results from its pivotal Phase 3 REBUILD clinical trial evaluating the safety and efficacy of INO

      6/5/23 7:00:00 AM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease

      WARREN, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that the last patient has completed blinded treatment in the ongoing Phase 3 REBUILD study of INOpulse®, a proprietary pulsatile nitric oxide delivery system, for the treatment of fibrotic interstitial lung disease (fILD). The Company expects to report top-line results from this study in mid-2023. "The successful and timely completion of the blinded treatment phase of our pivotal Phase 3 REBUILD trial represents a key milestone in our INOpulse® de

      5/11/23 8:30:42 AM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bellerophon Provides Clinical Program Update and Reports Full-Year 2022 Financial Results

      Completed Enrollment in INOpulse® REBUILD Phase 3 trial; Pivotal Top-line Data Expected in Mid-2023Signed License Agreement with Baylor BioSciences to Commercialize INOpulse® in Greater ChinaStrengthened Balance Sheet Through $5 Million Registered Direct Offering with Life Sciences-focused Institutional Investor WARREN, N.J., March 31, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the year ended December 31, 2022. "We have achieved significant recent pro

      3/31/23 8:30:00 AM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Puissance Capital Management Lp sold $111,776 worth of shares (1,076,841 units at $0.10), closing all direct ownership in the company (SEC Form 4)

      4 - Bellerophon Therapeutics, Inc. (0001600132) (Issuer)

      10/16/23 8:51:41 PM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Amin Naseem

      4 - Bellerophon Therapeutics, Inc. (0001600132) (Issuer)

      6/9/23 4:12:24 PM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Fernandes Peter

      4 - Bellerophon Therapeutics, Inc. (0001600132) (Issuer)

      6/9/23 4:12:06 PM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLPH
    SEC Filings

    See more
    • Bellerophon Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Bellerophon Therapeutics, Inc. (0001600132) (Filer)

      3/4/24 5:25:30 PM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Bellerophon Therapeutics Inc.

      DEFA14A - Bellerophon Therapeutics, Inc. (0001600132) (Filer)

      2/12/24 3:44:59 PM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Bellerophon Therapeutics Inc.

      DEFA14A - Bellerophon Therapeutics, Inc. (0001600132) (Filer)

      2/12/24 12:39:17 PM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLPH
    Financials

    Live finance-specific insights

    See more
    • Bellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease

      Trial did not meet its primary endpoint related to the change in moderate to vigorous physical activity INOpulse® was safe and well-tolerated, consistent with the overall safety profile demonstrated in Phase 2 and other INOpulse® programs in PH-COPD and PH-SarcoidosisCompany to host conference call and webcast with slides today at 8:30 AM ET WARREN, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced top-line results from its pivotal Phase 3 REBUILD clinical trial evaluating the safety and efficacy of INO

      6/5/23 7:00:00 AM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLPH
    Leadership Updates

    Live Leadership Updates

    See more
    • Bellerophon Provides Clinical Program Update and Reports Second Quarter 2021 Financial Results

      WARREN, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the second quarter ended June 30, 2021. "We continue to progress our INOpulse® inhaled nitric oxide therapy in multiple areas of significant unmet need," said Fabian Tenenbaum, Chief Executive Officer of Bellerophon. "Our ongoing pivotal Phase 3 REBUILD study for fibrotic interstitial lung disease, or fILD, patients at risk of associated pulmonary hypertension is progressing well and con

      8/5/21 8:30:00 AM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bellerophon Appoints Naseem Amin, M.D. as Chairman of its Board of Directors

      WARREN, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced the appointment of Naseem Amin, M.D., as Chairman of its Board of Directors, effective immediately. Dr. Amin, who has served as an Independent Director since 2015, will succeed Jonathan Peacock, who is retiring from the Company's Board. "It has been a privilege to work alongside the talented Bellerophon team over the past several years and to guide the Company's evolution into a late-stage development company," said Mr. Peacock. "With a number of

      5/26/21 8:30:00 AM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care